420 related articles for article (PubMed ID: 8952529)
1. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
[TBL] [Abstract][Full Text] [Related]
4. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung.
Jiang SX; Kameya T; Shinada J; Yoshimura H
Mod Pathol; 1999 Apr; 12(4):362-9. PubMed ID: 10229500
[TBL] [Abstract][Full Text] [Related]
5. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Iijima H; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Pathol Res Pract; 2008; 204(8):553-61. PubMed ID: 18440724
[TBL] [Abstract][Full Text] [Related]
6. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung.
Shabnam MS; Srinivasan R; Wali A; Majumdar S; Joshi K; Behera D
Lung Cancer; 2004 Aug; 45(2):181-8. PubMed ID: 15246189
[TBL] [Abstract][Full Text] [Related]
8. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.
Beasley MB; Lantuejoul S; Abbondanzo S; Chu WS; Hasleton PS; Travis WD; Brambilla E
Hum Pathol; 2003 Feb; 34(2):136-42. PubMed ID: 12612881
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
10. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
11. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
12. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis.
Farid P; Gomb SZ; Péter I; Szende B
Neoplasma; 2001; 48(4):299-301. PubMed ID: 11712682
[TBL] [Abstract][Full Text] [Related]
13. [Small cell carcinoma and carcinoids of the lung: morphology of apoptosis and expression of biomolecular markers of tumor growth].
Pal'tsev MA; Demura SA; Kogan EA; Jack G; Zende B
Arkh Patol; 2000; 62(5):11-7. PubMed ID: 11076293
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors.
Kobayashi Y; Tokuchi Y; Hashimoto T; Hayashi M; Nishimura H; Ishikawa Y; Nakagawa K; Sato Y; Takahashi A; Tsuchiya E
Cancer Sci; 2004 Apr; 95(4):334-41. PubMed ID: 15072592
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
17. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
[TBL] [Abstract][Full Text] [Related]
18. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.
Folpe AL; Gown AM; Lamps LW; Garcia R; Dail DH; Zarbo RJ; Schmidt RA
Mod Pathol; 1999 Jan; 12(1):5-8. PubMed ID: 9950155
[TBL] [Abstract][Full Text] [Related]
19. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
20. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma.
Eymin B; Gazzeri S; Brambilla C; Brambilla E
Oncogene; 2001 Mar; 20(14):1678-87. PubMed ID: 11313916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
